Teva expects about 25 percent of EpiPen market by year-end — Reuters: Top News

Teva Pharmaceutical Industries expects its generic version of Mylan’s EpiPen to have about 25 percent of the U.S. market by the end of 2019, Chief Executive Kare Schultz said on Tuesday.

via Teva expects about 25 percent of EpiPen market by year-end — Reuters: Top News